Early HIV Treatment Prolongs Life

One of the largest clinical drug trials has been stopped a year early because of the undeniably positive results. The federal health officials announced earlier this week that they were ending a clinical trial regarding early treatment for HIV because the trial results were clear early on.

The Centers for Disease Control and Prevention states there are several factors which prevent HIV-positive people from getting an early diagnosis, such as lack of insurance or wrong diagnosis. Dr. Demetre C. Daskalakis, the NYC health department’s assistant commissioner for H.I.V./AIDS prevention and control, says that treatment is being started quickly for newly diagnosed HIV patients in New York. Dr. Julio S. G. Montaner, a former president of the International AIDS Society, says early treatment is the best way to halt the AIDS epidemic.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below